Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy

JAMA Neurol. 2016 Mar;73(3):265-7. doi: 10.1001/jamaneurol.2015.4453.

Author

Raphael A Carandang¹

Affiliation

¹ Departments of Neurology, Anesthesiology, and Surgery, University of Massachusetts Medical School, Worcester2Departments of Neurology, Anesthesiology, and Surgery, UMass Memorial Medical Center, Worcester, Massachusetts.

PMID: 26810152
DOI: 10.1001/jamaneurol.2015.4453

No abstract available

Publication types

Comment

MeSH terms

Brain Ischemia / drug therapy
Fibrinolytic Agents / therapeutic use
Humans
National Institute of Neurological Disorders and Stroke (U.S.)*
Recombinant Proteins
Stroke / drug therapy
Thrombolytic Therapy
Tissue Plasminogen Activator / therapeutic use*
Treatment Outcome

Substances

Fibrinolytic Agents
Recombinant Proteins
Tissue Plasminogen Activator